Kalaris Therapeutics Inc (KLRS) Stock Overview
Explore Kalaris Therapeutics Inc’s financial performance, market position, analyst ratings, and future outlook.
Kalaris Therapeutics Inc (KLRS)
Key Financials
Key Financials
Market Cap
62.5M
P/E Ratio
-1.67
EPS (TTM)
$-2.15
ROE
-0.73%
KLRS Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Kalaris Therapeutics Inc (NASDAQ: KLRS) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Kalaris Therapeutics Inc's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of KLRS on the NASDAQ shows an RSI of 28.04, suggesting the stock is in a an oversold condition. Our forecasting models predict a 12-month price target of $10.31 for the NASDAQ listing.
Key metrics behind Kalaris Therapeutics Inc's NASDAQ-traded stock include a P/E ratio of -1.67 and a market capitalization of 62.5M. Combined with our AI analysis, these give both institutional and retail investors a clear view of KLRS on the NASDAQ.